II2 Stock Chart & Stats
€1.61
-€0.04(-1.52%)
At close: 4:00 PM EST
€1.61
-€0.04(-1.52%)
Day’s Range― - ―
52-Week Range€0.47 - €2.36
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€28.08M
Enterprise Value€26.31M
Total Cash (Recent Filing)€41.57M
Total Debt (Recent Filing)€3.11M
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Aug 11, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding46,838,963
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.37
Price to Sales (P/S)14.56
P/FCF Ratio-3.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.23Price Target Upside100.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.63
Revenue Forecast (FY)€10.69M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Margin ImprovementExceptional top-line momentum (+122% YoY in Q1 2026) alongside improving gross margins (GAAP 20.2%, adjusted 34.1%) indicates accelerating product adoption and improving unit economics. If sustained, this trend reduces structural financing pressure and supports scaling commercial investment.
Large Clinical Installed Base & Strong Trial DataA global installed base >70,000 and pristine 30-day CGUARDIANS II outcomes create durable clinical credibility and physician preference. That clinical moat supports international sales, accelerates adoption if U.S. approvals arrive, and strengthens competitiveness in carotid/TCAR markets.
Low Financial Leverage & Manufacturing ReadinessVery low leverage (debt ~ $2M) provides balance sheet flexibility, while stated manufacturing readiness reduces execution risk after regulatory clearance. Together these structural strengths lower the need for immediate debt financing and support scalable commercialization post-approval.
Bears Say
Severe Cash BurnSustained negative operating and free cash flow of roughly -$38.6M and -$40.1M TTM respectively indicate heavy structural cash burn. Without substantial revenue scale or cost rebalancing, the company will need recurring financing, increasing dilution and execution risk over the medium term.
U.S. Recall And Commercial PauseThe U.S. pause/recall halts commercialization in a key market and creates timing uncertainty for relaunch (management cites possible 90–100 day pause or regulatory-design choices). That delays revenue recovery, disrupts physician adoption momentum, and impairs near-term scale in the large U.S. TCAR market.
Capital Dependence And Dilution RiskApproval to increase authorized shares and a $75M at-the-market program signal likely future equity issuance given current burn. Reliance on the equity markets increases dilution risk and ties future operational continuity to access to capital, a structural constraint on shareholder value.
InspireMD News
II2 FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was €0.47 and its highest was €2.36 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is €28.08M.
When is InspireMD’s upcoming earnings report date?
InspireMD’s upcoming earnings report date is Aug 11, 2026 which is in 40 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on May 04, 2026. The company reported -€0.141 earnings per share for the quarter, beating the consensus estimate of -€0.158 by €0.018.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -0.18.
How many shares outstanding does InspireMD have?
InspireMD has 46,838,963 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -€0.141 in its last earnings report, beating expectations of -€0.158. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in DE:II2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InspireMD Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.23 (100.47% Upside)
€3.23 (100.47% Upside)
Insider Transactions
Bought Shares
Worth €154.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.79%
12-Months-Change
Fundamentals
Return on Equity
-81.52%
Trailing 12-Months
Asset Growth
46.03%
Trailing 12-Months
Company Description
InspireMD
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
II2 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong commercial traction and substantial year-over-year revenue growth (122%), expanding international sales (48% YoY), a large clinical installed base (>70,000 cases), and clear regulatory/clinical pathways (C-GUARDIANS III initiation, expected approvals). Offsetting these positives is a material near-term operational setback — a voluntary U.S. pause/recall of the CGuard Prime 135 delivery system — which led to impairment charges, planned reserves (~$1.35M combined), withdrawal of 2026 revenue guidance, increased operating expenses, and reduced cash versus year-end. Management characterizes the issue as technical (not implant safety), has identified root causes, and expects a path to remediation and relaunch, but timing is uncertain. Overall, the call balances strong growth and long-term opportunity with a meaningful short-term commercial disruption and financial impact.View all DE:II2 earnings summariesII2 Stock 12 Month Forecast
Average Price Target
€3.23
▲(100.47% Upside)
Technical Analysis
Options Prices
Currently, No data available
---